Profile data is unavailable for this security.
About the company
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based company mainly engaged in the production, sales and service of chemical raw materials and intermediates. The Company is committed to providing one-stop customized pharmaceutical contract development and manufacturing organization (CDMO) services to global pharmaceutical companies, biotechnology companies, scientific research institutions, and others, including small molecule chemical drugs, peptide drugs, conjugated drugs and small nucleic acid drugs. The CDMO projects served by the Company involve therapeutic areas such as anti-tumor, anti-heart failure, anti-depression, treatment of Parkinson's disease, anti-lung cancer, anti-virus, anti-diabetes, and anti-respiratory system infection.
- Revenue in CNY (TTM)5.18bn
- Net income in CNY619.54m
- Incorporated1998
- Employees5.00k
- LocationZhejiang Jiuzhou Pharmaceutical Co LtdNo.99, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
- Phone+86 57 688706789
- Fax+86 57 688706788
- Websitehttps://www.jiuzhoupharma.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.61bn | 748.99m | 12.99bn | 2.44k | 17.24 | 3.92 | -- | 3.59 | 1.33 | 1.33 | 6.41 | 5.84 | 0.6952 | 2.15 | 10.07 | 1,483,590.00 | 14.41 | 11.90 | 23.44 | 18.89 | 74.86 | 74.36 | 20.73 | 16.46 | 0.8157 | -- | 0.0259 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Shanghai Yizhong Pharmaceutical Co Ltd | 175.86m | -8.02m | 13.37bn | 65.00 | -- | 9.34 | -- | 76.00 | -0.0382 | -0.0382 | 0.8583 | 6.93 | 0.1141 | 0.5926 | 1.87 | 2,705,569.00 | -0.5202 | 5.44 | -0.5474 | 5.64 | 86.51 | 92.99 | -4.56 | 36.90 | 17.73 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 689.61m | -115.42m | 13.78bn | 1.06k | -- | 8.83 | -- | 19.99 | -0.2829 | -0.2829 | 1.69 | 3.83 | 0.2114 | 2.07 | 5.09 | 650,574.50 | -3.54 | 0.0036 | -4.06 | 0.0042 | 84.87 | 91.31 | -16.74 | 0.0181 | 2.25 | -3.86 | 0.4746 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| Jiang Zhong Pharmaceutical Co Ltd | 4.39bn | 806.33m | 13.96bn | 4.18k | 17.23 | 3.33 | -- | 3.18 | 1.28 | 1.28 | 6.94 | 6.59 | 0.6649 | 4.27 | 11.24 | 1,050,250.00 | 13.36 | 11.45 | 20.45 | 16.72 | 61.86 | 64.04 | 20.10 | 18.23 | 1.71 | -- | 0.0006 | 93.25 | -2.59 | 12.61 | 9.67 | 11.20 | 30.67 | 36.85 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.18bn | 619.54m | 14.63bn | 5.00k | 23.77 | 1.67 | -- | 2.83 | 0.6919 | 0.6919 | 5.83 | 9.82 | 0.4446 | 1.99 | 3.57 | 1,034,815.00 | 5.33 | 9.23 | 6.74 | 12.19 | 33.67 | 33.78 | 12.00 | 15.64 | 2.28 | -- | 0.0768 | 39.55 | -6.57 | 20.67 | -41.34 | 20.58 | 22.64 | 8.45 |
| Zhejiang Medicine Co Ltd | 9.38bn | 1.46bn | 14.69bn | 5.82k | 10.08 | 1.33 | -- | 1.57 | 1.52 | 1.52 | 9.76 | 11.51 | 0.6973 | 2.74 | 5.88 | 1,613,318.00 | 9.86 | 5.31 | 12.27 | 6.93 | 43.79 | 36.97 | 14.14 | 7.68 | 2.00 | -- | 0.0709 | 30.91 | 20.29 | 5.88 | 170.11 | 27.62 | 3.74 | -18.03 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 10.42bn | 1.11bn | 14.78bn | 11.47k | 13.27 | 1.09 | -- | 1.42 | 0.8305 | 0.8305 | 7.77 | 10.11 | 0.5319 | 2.95 | 8.33 | 908,376.50 | 6.79 | 5.14 | 9.93 | 8.21 | 37.11 | 40.86 | 12.76 | 7.82 | 2.68 | -- | 0.0494 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.69bn | 546.88m | 14.93bn | 7.99k | 26.06 | 1.75 | -- | 1.54 | 0.4777 | 0.4777 | 8.46 | 7.12 | 0.5797 | 2.96 | 5.09 | 1,212,416.00 | 3.24 | 2.33 | 5.51 | 4.32 | 45.30 | 41.26 | 5.59 | 3.99 | 0.6813 | 8.16 | 0.3457 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Tonghua Dongbao Pharmaceutical Co Ltd | 2.07bn | -148.24m | 15.61bn | 3.41k | -- | 2.40 | -- | 7.54 | -0.0855 | -0.0855 | 1.10 | 3.32 | 0.268 | 0.8435 | 3.34 | 606,930.10 | -1.97 | 14.89 | -2.13 | 15.68 | 70.37 | 78.86 | -7.35 | 35.26 | 1.85 | -- | 0.1124 | 50.60 | -34.66 | -6.27 | -103.66 | -- | 14.17 | 4.56 |
Data as of Jul 11 2025. Currency figures normalised to Zhejiang Jiuzhou Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2024 | 34.32m | 3.82% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2024 | 17.50m | 1.95% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2024 | 7.68m | 0.86% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2024 | 6.38m | 0.71% |
| China Fund Management Co., Ltd.as of 31 Dec 2024 | 6.18m | 0.69% |
| GF Fund Management Co., Ltd.as of 31 Dec 2024 | 6.02m | 0.67% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2024 | 5.27m | 0.59% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2024 | 5.25m | 0.59% |
| China Asset Management Co., Ltd.as of 31 Dec 2024 | 3.65m | 0.41% |
| E Fund Management Co., Ltd.as of 31 Dec 2024 | 2.89m | 0.32% |
More ▼
Data from 31 Dec 2024 - 30 Apr 2025Source: FactSet Research Systems Inc.
